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Background: The purpose of this study is to present our first results of sentinel node analysis (SLN) by one step
nucleic acid amplification (OSNA) in routine clinical practice in our centre and compare them with the results of
classic histopathological analysis in a historical cohort from our same institution.
Methods: 407 patients (total study population) with early breast cancer and no clinical nodal involvement
underwent SLN biopsy in our institution. The SLN was analysed by OSNA in 164 biopsies. OSNA results were
compared with the conventional histopathology study of 244 patients who had undergone SLN biopsy previously.
The characteristics of the patients in both groups were evaluated and a comparison was made of the rate of
metastases detected by both methods and of the surgical procedures needed in each group. We also investigated
the state of non-sentinel lymph nodes if micrometastases where found in SLN.
Results: SLN biopsy result was considered as positive in 45 patients (28%) in the OSNA group and in 58 in the
historical group (24%). There was no difference in the rate of macrometastases (16,5% for OSNA, 20% for HE) but
we found differences in the rate of micrometastases (11% for OSNA and 3,6% for HE p = 0.0007). Axillary
lymphadenectomy (ALND) was performed in 43/45 cases in the OSNA group and in 51/58 of the historical group.
In all patients diagnosed by OSNA, ALND was performed during the initial surgical procedure. In the historical
cohort ALND was performed during the initial surgical procedure in 41 patients and in a second surgical procedure
in 10 patients. Patients from both groups with micrometastases in the SLN had no metastases in other nodes when
the ALND was performed.
Conclusions: OSNA analysis allows the detection of SLN metastases as precisely as conventional pathology with an
increased detection of micrometastases. The OSNA method can reduce the need of a deferred lymphadenectomy.
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Selective sentinel node biopsy has replaced axillary
lymph node dissection due to its lower morbidity and
equivalent prognosis in the long-term (Giuliano et al.
1997; Krag et al. 2010). The presence of nodal metastases
is an important prognostic factor and it can help in the
asssessment of the need for adjuvant therapy after surgery.
The conventional approach in the study for nodal* Correspondence: delacueva_hel@gva.es
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in any medium, provided the original work is pmetastases has been staining with haematoxylin-eosin
(HE) and immunohistochemistry (IHC). This technique
allows analysis during the primary breast tumour surgery,
with some sections of the node analysed during the pri-
mary procedure, although the remaining sections have
to be studied in a deferred manner, which increases the
risk of losing valuable information during the surgical
procedure.
The one-step acid amplification method (OSNA) de-
tects and quantifies by polymerase chain reaction (PCR)
the presence of mRNA of cytokeratin 19 in the whole
node (Tsujimoto et al. 2007). It is more time-consumingis an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.







Age, median (range) 58 (33–86) 57 (30–93)
Pathologic tumour size,
mean (range) mm
16.63 (0–60) 14.16 (0–55)
Tumour histology DCIS 12 8
Ductal invasive 131 192








Oestrogen receptor Positive 142 143
Negative 21 25
Progesterone receptor Positive 125 202
Negative 38 42
HER2 status Positive 15 4
Negative 139 26
Unknown 9 214
Ki 67 ≤ 10% 80 95
> 10% 73 124
Unknown 10 25
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tively (Osako et al. 2011; Sagara et al. 2011).
The purpose of this study is to present our first results
with the OSNA assay performed in a routine clinical set-
ting in 163 patients with invasive and in situ breast cancer,
examine their consistency with the classic HE study and
evaluate the potential implications for the locorregional
treatment of breast cancer patients.
Patients and methods
Patients
In the Hospital Universitari i Politècnic La Fe of Valencia
164 consecutive sentinel node biopsy procedures were
performed in 163 patients with in situ and early breast can-
cer between March 2006 and December 2011, studied by
OSNA technique. This analysis was performed intraopera-
tively and if metastases (both micro or macrometastases)
were found axillary lymphadenectomy was practiced at
the same time. This study has received the approval of the
ethical local committee (Comité Ético de Investigación
Científica del Hospital La Fe).
For comparison, 244 controls were used as a historical
cohort; they were treated between March 2000 and April
2007 in the same hospital, and their sentinel node analysis
was performed by the HE and immunohistochemical
method.
In both groups, the criteria for sentinel node biopsy
were: tumours up to 5 cm in size with no clinical involve-
ment according to physical examination and ultrasound of
the axilla. Table 1 shows the patient characteristics. Statis-
tical analysis was performed with SPSS software, using the
Chi square statistical test for associations between param-
eters of interest.
Study of SLN by OSNA
After the fatty tissue was removed, the SLN was weighed
and whole SLN was processed for the OSNA assay,
which is based on the principles of the reverse transcrip-
tion loop-mediated isothermal amplification method. The
SLN was homogenized using LYNORHAG lysis buffer
(Sysmex Corp., Hyogo, Japan). CK19 mRNA in each lysate
was amplified using a LYNOAMP BC gene amplification
reagent (Sysmex Corp.), then a 2-μl sample of each lysate
was subjected to an RT-LAMP reaction. The CK19 mRNA
copy number was detected by measuring the rise time
based on a standard curve using an RD-100i (Sysmex
Corp.).
The SLN was assessed as OSNA - when the CK 19
mRNA copy number was fewer than 2.5 × 102 copies μl,
OSNA + when it was between 2.5 × 102 and 5.0 × 103
copies μl, and OSNA ++ when it was more than 5.0 ×
103 copies μl. The OSNA assay is sometimes inhibited
by inhibitory materials resulting in false negative (< 250
copies μl) reactions that may be resolved as positive (≥ 250copies μl) reactions by simple dilution (1:10). However,
the values of these reactions after dilution are less reliable
for the quantitative assessment and were evaluated as +
inhibition (+I).
Study of sentinel node by IHC
The classical pathological study was based on a first-time
intraoperative evaluation. The node was frozen and serial
sections of the node, approximately 2 mm each, were
performed. Histological staining of each section was done
with haematoxylin-eosin. Subsequently, all complete node
sections were fixed in paraffin and histological cuts were
performed in intervals of 200 microns, which allowed for
immunohistochemical staining with cytokeratin AE1-3
and Cam 5.2 and for the detection of isolated tumour
cells.
To classify the findings in the lymph node the defin-
ition published in the seventh edition of the AJCC was
used, which differentiates isolated tumour cells up to
0.2 mm in maximum diameter detected by immunohis-
tochemistry [ITC or pN0 (i +)], tumour cells groups of
more than 0.2 mm and up to 2 mm in diameter
(micrometastases or pN1mi) and tumour cell groups
with more than 2 mm (macrometastases or pN1a).
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Analysis of sentinel node
The incidence of lymph node metastases in the OSNA
group was 45 (28%): 27 cases of macrometastases (17%)
and 18 micrometastases (11%). In the conventional IHC
control group any kind of metastases were found in 71
cases (29%): 49 patients showed macrometastases (20%),
9 micrometastases (4%), and 13 presented ITC (5%).
Macrometastases rate differences were not statistically
significant. Conversely, the difference in proportion of
micrometastases is significant, with an increase of detec-
tion rate within the OSNA group (11 vs 4%, p = 0.007).
Axillary lymphadenectomy in first vs. second time
Regarding the axillary surgery performed, all 18 OSNA
patients who had micrometastases underwent axillary
lymphadenectomy in the same surgical procedure, except
in the case of a woman operated for bilateral breast cancer
in whom there were micrometastases in the sentinel nodes
of both sides and only a left axillary dissection was
performed. In 26 of the 27 patients with macrometastases,
a lymphadenectomy was performed during the initial
surgery, while for one patient no further surgery was
done.
Of the 49 women with macroscopically involved nodes
in the historical cohort 41 underwent ALND at the same
time as the SLN procedure while in the remaining 8 the
axillary clearance was performed later, as the results
were obtained after the operation. Of the 9 patients with
micrometastases ALND was performed in a second time
in two patients (these were two women whose primary
tumour had to be re-excised due to close surgical mar-
gins); the other 7 did not undergo any other axillary
surgical procedure.
Analysis of non-sentinel lymph nodes in patients with
micrometastases in the SLNB
After extending the number of axillary nodes analysed with
axillary lymphadenectomy in patients with micrometastases
in the SLN biopsy (2/9 patients in the historical cohort
and 17/18 OSNA), there were no more affected lymph
nodes outside the sentinel lymph node.
Discussion
The sentinel node study by the OSNA method is being ap-
plied in an increasing number of hospitals. Its advantages
over the traditional approach with haematoxylin-eosin
and immunohistochemistry (HE/IHC) include the de-
crease in the workload for the pathologist as the process is
largely automated and the ability to analyse the full node
instead of just some sections while performing surgery of
the primary breast tumour.
Different studies have shown that the OSNA assay has a
good correlation with the pathological study (Tsujimotoet al. 2007; Sagara et al. 2011; Li et al.; Tamaki et al. 2009),
and it also has a higher sensitivity for the detection of
micrometastases (Osako et al. 2011).
In our series we have found a similar rate of macro-
metastases in SLN analysed by OSNA and HE/IHC but
with an increased detection of micrometastases with
OSNA.
However, this increase in the number of nodes with
micrometastases provides information that is difficult to
apply in the clinical setting, as its prognostic value has
not been fully clarified. One of the most relevant studies
to address this issue is the prospective NSABP B-32 trial,
which was designed to evaluate the outcome of SLN
biopsy alone compared to axillary dissection, in which
5,611 patients with SLN biopsy were randomized to
undergo or not to undergo axillary clearance (Krag et al.
2007). Subsequently, an analysis was published of pa-
tients with occult nodal metastases reviewing almost
4000 ganglion blocks (Weaver et al. 2011). At five years,
the presence of occult metastases was associated with a
lower overall survival, progression free survival and dis-
tant metastases free interval compared to node-negative
patients. Although this increased risk in the three pa-
rameters was statistically significant, the magnitude of
the difference in the 5-year Kaplan-Meier estimates of
overall survival was only 1.2 percentage points and the
authors concluded that this difference might be of little
clinical relevance.
The finding of micrometastases in the sentinel node
can have an impact on clinical management. In our
series all patients with micrometastases in the OSNA
group underwent axillary clearance. One of the reasons
why it was done was the study of a possible involve-
ment of other lymph nodes, which is estimated to
occur in approximately 10-15% of cases of SLN biopsy
micrometastases in classical histological studies (Solá
et al. 2013; Galimberti et al. 2013; Cserni et al. 2004;
Houvenaeghel et al. 2009). In this sense, we cannot
draw conclusions from our data since the rate of
micrometastases in the HE/IHC group was very low
and barely any lymphadenectomies were performed.
Published data about the OSNA technique also indi-
cate that the PCR load of cytokeratin 19 correlates with
the finding of non-sentinel node metastases (Osako
et al. 2011), although in our sample none of 17 patients
undergoing lymphadenectomy due to micrometastasis
in OSNA had involvement in the other nodes.
Despite the possible presence of other affected lymph
nodes there are trials showing that lymphadenectomy
can be omitted in patients with micrometastases in the
SLN biopsy since their presence does not increase the
rate of axillary recurrence (Solá et al. 2013; Galimberti
et al. 2013; Guenther et al. 2003; Gant et al. 2003;
Langer et al. 2005). Recently, two randomised trials that
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(Solá et al. 2013) and the IBCSG 23–01 trial (Galimberti
et al. 2013). With a recruitment lower than expected,
247 and 932 patients respectively with micrometastases
in SLN biopsy were randomly assigned to axillary dis-
section or no axillary dissection. No differences in terms
of disease-free survival after a follow-up of five years
were seen.
Probably the long-term monitoring of patients in
which micrometastases are detected by OSNA will pro-
vide new data in this sense, as it is a method that is
more reproducible and allows a more complete analysis
of the node than the histopathological analysis (Osako
et al. 2011; Tamaki et al. 2009).
Currently in our centre micrometastases in SLN biopsy
are not considered an indication for axillary clearance,
given the growing literature that supports this decision
and the recommendations in this sense of the 2011 St
Gallen Consensus Conference (Goldhirsch et al. 2011).
We maintain the indication in case of macrometastases
although in the future this might be avoided in cases of
macrometastases in only one or two sentinel nodes in
certain patient, based on the findings of the ACOSOG
Z0011 study (Giuliano et al. 2011).
In any case, the full analysis of lymph nodes by OSNA
allows us to perform lymphadenectomy in the same surgi-
cal procedure in all cases, something not always possible
in patients studied by IHC in which the full results can be
obtained later. The performance of a single procedure can
provide important advantages for the patient, such as
avoiding a second operation and a possible delay in the
start of adjuvant therapy, as well as lower cost for the
institution (Guillen-Paredes et al. 2011).
Conclusions
The sentinel node analysis by OSNA enables reliable re-
sults within minutes, allowing axillary lymphadenectomy
practice in the same surgery when indicated, i.e. in case of
SLN biopsy macrometastases.
The increase in diagnoses of patients with micro-
metastatic involvement by OSNA should be studied in
terms of its prognostic and therapeutic implications.
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